Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01423149 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization
Myopia, Degenerative

Interventions

DRUG: Combretastatin A-4 Phosphate

Sponsor

Mateon Therapeutics